Item no. |
LEIN-C1970-100ug |
Manufacturer |
Leinco Technologies
|
Amount |
100 ug |
Quantity options |
100 ug
200 ug
50 ug
|
Category |
|
Type |
Antibody Primary |
Applications |
FC |
Clone |
SJ25-C1 |
Specific against |
Human (Homo sapiens) |
Host |
Mouse |
NCBI |
930 |
ECLASS 10.1 |
32160702 |
ECLASS 11.0 |
32160702 |
UNSPSC |
12352203 |
Shipping condition |
Cool pack |
Available |
|
Manufacturer - Category |
Primary Monoclonal Antibodies>SurfaceTag Human CD Markers |
Manufacturer - Targets |
CD19 |
Country of Origin |
USA |
Shipping Temperature |
Next Day 2-8°C |
Storage Conditions |
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. |
Product Description |
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling. |
Background |
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling. |
PubMed |
CD19 |
Excitation Laser |
Blue Laser (493 nm) |
Ligand/Receptor |
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor |
Manufacturer - Research Area |
Costimulatory Molecules, Immunology |
Manufacturer - Specificity |
Clone SJ25-C1 recognizes an epitope on human CD19. |
RRID |
AB_2829055 |
Concentration |
0.2 mg/ml |
Formulation |
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
Antigen Distribution |
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. |
Immunogen |
NALM1 + NALM16 cells |
Additional Information |
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.